论文部分内容阅读
目的:探讨枸杞多糖对原发性肝癌患者血清中甲胎蛋白(AFP)、人肝癌抗原(PHCA)、血管内皮生长因子(VEGF)及结缔组织生长因子(CTGF)水平的影响。方法:选取我院诊治的原发性肝癌患者84例为研究对象,根据治疗方案分为两组,其中对照组41例给予肝动脉化疔栓塞术(TACE)治疗,实验组43例在对照组基础上给予枸杞多糖治疗。用酶联免疫吸附法对两组患者治疗前后血清中VEGF、CTGF及PHCA水平进行检测,应用电化学发光法对AFP进行检测,并比较两组患者的临床疗效。结果:干预前,两组的AFP以及PHCA水平无显著差异(P>0.05);干预后,实验组AFP及PHCA水平显著低于对照组,差异具有统计学意义(P<0.05);干预后,实验组患者VEGF和CTGF下降幅度显著明显高于对照组,差异具有统计学意义(P<0.05);干预后,实验组治疗有效率(76.74%)显著高于对照组(60.98%),差异具有统计学意义(P<0.05)。与同期对照组比较,实验组生存率较高,不良反应发生率较低,差异具有统计学意义,P<0.05。结论:枸杞多糖能够降低原发性肝癌患者的血清AFP、PHCA、VEG以及CTGF水平,提高原发性肝癌治疗效果。
Objective: To investigate the effects of Lycium barbarum polysaccharides on serum levels of AFP, PHCA, VEGF and CTGF in patients with primary liver cancer. Methods: Totally 84 patients with primary hepatocellular carcinoma (HCC) diagnosed and treated in our hospital were enrolled in this study. They were divided into two groups according to the treatment regimen: 41 cases in the control group were given TACE, 43 cases in the control group On the basis of lycium barbarum polysaccharide treatment. Serum levels of VEGF, CTGF and PHCA were detected by enzyme-linked immunosorbent assay (ELISA) before and after treatment. AFP was detected by electrochemiluminescence and the clinical efficacy was compared between the two groups. Results: Before intervention, there was no significant difference in AFP and PHCA levels between the two groups (P> 0.05). After intervention, the levels of AFP and PHCA in the experimental group were significantly lower than those in the control group (P <0.05) The decrease of VEGF and CTGF in the experimental group was significantly higher than that in the control group (P <0.05). After the intervention, the effective rate of the experimental group (76.74%) was significantly higher than that of the control group (60.98%), Statistical significance (P <0.05). Compared with the control group at the same period, the survival rate of the experimental group was higher, the incidence of adverse reactions was lower, the difference was statistically significant, P <0.05. CONCLUSION: LBP can reduce serum AFP, PHCA, VEG and CTGF levels in patients with primary liver cancer and improve the therapeutic effect of primary liver cancer.